An observational study in Pregnancy; Nutritional Diseases, sponsored by University of Kansas Medical Center. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-08.
Sponsored by University of Kansas Medical Center · Observational
Among 61 studies in Gestational Weight Gain with a site in United States — 12 open to participants now, 15 under way, none of them phase 3. Gestational Weight Gain · United States.
Among the 61 studies in Gestational Weight Gain with a site in United States, this one is one of 5 that started in 2017, is one of 6 observational ones, and was the 19th registered.
134 studies on the registry are indexed under Gestational Weight Gain; 24 are open to participants now.
Browse Gestational Weight Gain studies →12 of the 61 studies in Gestational Weight Gain with a site in United States are open now. Recruiting first, the newest first:
San Diego State University · Sites in United States
Ages 18+ · Women only
Texas A&M University · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
University of Kansas Medical Center · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
State University of New York at Buffalo · Sites in United States
Ages 18+ · Women only
University of Arkansas · Sites in United States
Ages 16–44 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 21 Gestational Weight Gain studies recruiting now, 7 (33%) set no upper age limit and 14 (67%) stop at 75 or younger; 4 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 5 started in 2017.
This study's enrollment of 254 is below the median of 429 across 22 observational studies indexed under Gestational Weight Gain.
Median enrollment 70 across the 55 interventional studies, 327 across the 6 observational. Of the 43 that completed or were terminated, 18 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 61 has an industry lead sponsor. The 10 most frequent:
University of Kansas Medical Center is the lead sponsor of 492 studies on the registry; 110 are open to participants now.
Of its 38 completed or terminated interventional studies of FDA-regulated products, 24 (63%) have results posted.
University of Kansas Medical Center has 5 studies filed under Gestational Weight Gain — fewer than ten, so there is no comparison to draw.
5 of the studies in Gestational Weight Gain with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05518604Tripler Army Medical CenterWeight Loss and Physical Fitness Following Pregnancy in Active Duty Women | 2026-12-01 |
| NCT05619705Johns Hopkins UniversityHealthy for Two-Home Visiting (H42-HV): Health Coaching for Pregnant Women | 2026-12-15 |
| NCT05674799Wake Forest University Health SciencesNDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks | 2027-05-31 |
| NCT06666257Arkansas Children's Hospital Research InstituteContinuous Glucose and E-Monitoring to Support Healthy Weight Gain in Pregnancies - The GEM Study | 2027-07-30 |
| NCT07792837San Diego State UniversityAn Online Intuitive Eating Program for Pregnant Women With Obesity to Support Well-Being | 2027-08 |
Add all 5 to your calendar (.ics) → With an account.
Among the 61 studies in Gestational Weight Gain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn if participants in the ADORE study (NCT02626299), who took a DHA supplement during pregnancy, see favorable body fat in their infants from birth to 24 months, and if excessive or appropriate weight gain during pregnancy impacts this result.
Participants are invited from those already participating in the parent study, ADORE.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants for this study are invited from the parent study, ADORE. Eligibility listed reflects criteria for the ADORE study.
Inclusion Criteria:
Exclusion Criteria:
Participants enrolled in the ADORE study that were randomly assigned to the 200 mg/day group that consented to participate in ADORE-GAINS.
Participants enrolled in the ADORE study that were randomly assigned to the 1000 mg/day group that consented to participate in ADORE-GAINS.
Infant Fat Mass (FM)
Difference in FM in offspring exposed to high vs. low DHA and excessive vs. non-excessive GWG
Time frame: 24 months
Central Fat Mass
Difference in FM in offspring exposed to high vs. low DHA and excessive vs. non-excessive GWG
Time frame: 24 months
| Milestone | 200 MG/DAY | 1000 MG/DAY |
|---|---|---|
| Started | 126 | 128 |
| Completed | 111 | 111 |
| Not completed | 15 | 17 |
| Withdrew: Lost to follow-up | 15 | 17 |
Difference in FM in offspring exposed to high vs. low DHA and excessive vs. non-excessive GWG
| g | 200 MG/DAY | 1000 MG/DAY |
|---|---|---|
| Infant Fat Mass (FM) | 3050.7 (2697.3 to 3404.1) | 3673.6 (3248.6 to 4098.7) |
Difference in FM in offspring exposed to high vs. low DHA and excessive vs. non-excessive GWG
| g | 200 MG/DAY | 1000 MG/DAY |
|---|---|---|
| Central Fat Mass | 1085.3 (934.3 to 1236.2) | 1377.3 (1195.8 to 1558.8) |
Collected over Collected for the duration of study visits, 24 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 200 MG/DAY | 0/124 (0%) | 0/124 (0%) | 0/124 (0%) |
| 1000 MG/DAY | 0/126 (0%) | 0/126 (0%) | 0/126 (0%) |
| Age, Continuous(years) | ADORE- 200 mg/Day | ADORE - 1000 mg/Day | Total |
|---|---|---|---|
| Mean | 30.4 ± 5.1 | 31.3 ± 5.6 | 30.9 ± 5.3 |
| Sex: Female, Male(Participants) | ADORE- 200 mg/Day | ADORE - 1000 mg/Day | Total |
|---|---|---|---|
| Female | 126 | 128 | 254 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | ADORE- 200 mg/Day | ADORE - 1000 mg/Day | Total |
|---|---|---|---|
| Maternal Race and Ethnicity — American Indian or Alaska Native | 1 | 0 | 1 |
| Maternal Race and Ethnicity — Asian | 0 | 5 | 5 |
| Maternal Race and Ethnicity — Black or African American | 13 | 10 | 23 |
| Maternal Race and Ethnicity — Hispanic | 43 | 53 | 96 |
| Maternal Race and Ethnicity — White | 66 | 59 | 125 |
| Maternal Race and Ethnicity — More than one race | 3 | 1 | 4 |
| DHA mean % of RBC Total Fatty Acids(percent of total fatty acids in RBC) | ADORE- 200 mg/Day | ADORE - 1000 mg/Day | Total |
|---|---|---|---|
| Mean | 6.5 ± 1.7 | 6.1 ± 1.6 | 6.3 ± 1.6 |
| Body Mass Index (BMI)(kg/m^2) | ADORE- 200 mg/Day | ADORE - 1000 mg/Day | Total |
|---|---|---|---|
| Mean | 28.2 ± 6.9 | 29.1 ± 8.1 | 28.7 ± 7.5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2017 to primary completion in Aug 2022, 57 months.
Results were first posted in Oct 2024, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Kansas Medical Center →